References
- Camu F, Beecher T, Recker DP, Verburg KM. (2002). Valdecoxib a COX-2-specific inhibitor is an efficacious opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther, 9:43–51.
- Fricke J, Varkalis J, Zwillich S, Adler R, Forester E, Recker DP, . (2002). Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther, 9:89–97.
- Donnelly MT, Hawkey CJ. (1997). COX-2 inhibitors—a new generation of safer NSAIDs. Aliment Pharmacol Ther, 11:227–36.
- Pennisi E. (1998). Building better aspirin and does aspirin ward off cancer and Alzheimer's. Science, 280:1191–2.
- Vane JR, Bakhle YS. (1998). Botting RM. Cyclooxygense 1 and 2. Annu Rev Pharmacol Toxicol, 38:97–120.
- Isakson PC, Zweifel BS, Masferrer JL, Koboldt C, Seibert K, Hubbard RC, (1998). Specific COX-2 inhibitors: From bench to bedside. In: Vane J, Botting J, eds. Pharmacology, clinical effects and therapeutic potential, London: Kluwer Academic Publishers and William Harvey Press, 127–33.
- Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, . (1998). Preliminary study of the safety and efficacy of SC-58635 a novel cycolooxygenase 2 inhibitor. Arthritis Rheum, 41:1591–1602.
- Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. (2000). In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. J Microencapsul, 17(2):145–55.
- Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. (2000). Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro/in vivo evaluation. Int J Pharm, 195(1–2):179–88.
- Puebla P, Pastoriza P, Barcia E, Fernandez-Carballido A. (2005). PEG-derivative effectively modifies the characteristics of indomethacin-PLGA microspheres destined to intra-articular administration. J Microencapsul, 22(7):793–808.
- Srinath P, Chary MG, Vyas SP, Diwan PV. (2000). Preparation and pharmacodynamic evaluation of liposomes of indomethacin. Drug Dev Ind Pharm, 26(3):313–21.
- Srinath P, Chary MG, Vyas SP, Diwan PV. (2000). Long-circulating liposomes of indomethacin in arthritic rats—a biodisposition study. Pharm Acta Helv, 74(4):399–404.
- Rajendrakumar K, Madhusudan S, Pralhad T. (2005). Cyclodextrin complexes of valdecoxib: Properties and anti-inflammatory activity in rat. Eur J Pharm Biopharm, 60(1):39–46.
- Agnihotri SM, Vavia PR. (2006). Effects of formulation variables on the formation of nanoparticles prepared from L-lactide-depsipeptide copolymer. J Biomed Nanotech, 2(3–4):239–44.
- Tuncay M, Alis SC, Kas HS, Ercan MT, Peksoy I, Hincal AA. (2000). Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro: In vivo evaluation. Int J Pharm, 195:179–88.
- Ramakrishna NVS, Vishwottam KN, Wishu S, Koteshwara M. (2004). Quantitation of valdecoxib in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection using liquid-liquid extraction. J Chromatogr B, 802(2):271–5.
- Casley-Smith JR. (1964). An electron microscopic study of injured and abnormally permeable lymphatics. Ann NY Acad Sci, 116:803–30.
- Naeff R, Pliska V, Weder HG. (1990). Pharmacokinetics of small unilamellar liposomes and incorporated lonazolac after i.m. administration. J Microencapsulation, 7(1):95–103.
- Pandey R, Khuller GK. (2004). Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother, 54:266–8.